$Strategy(MSTR)$ Holding MSTR continues to pay off! Proves Buffett's wisdom once again: understand what you own and hold for the long term. Perfectly timed with the contra688 offer - a sweet bonus for getting started! Bullish for the next decade.
$SoundHound AI Inc(SOUN)$ Breakout mode! SOUN is testing its previous high with strong volume, fueled by the booming AI voice market. If it holds this level, the sky's the limit. Ready for takeoff!
$Tempus AI(TEM)$ 's healthcare AI momentum building! Genomic analysis hot with FDA tailwinds - volatility can't hide the uptrend. Holding for the big breakout!
$Apple(AAPL)$ A small win on Apple this round—not a huge jump, but holding a core tech giant like this just feels solid. With AI rollout and hardware upgrades, fundamentals remain strong. Still bullish!
$SPDR S&P MidCap 400 ETF Trust(MDY)$ posted a steady $346 gain in one day, highlighting the strength of mid-cap stocks. The SPDR S&P MidCap 400 ETF rose from $565.46 to $579.34, delivering a 2.5% daily gain and $346.52 in profits. This trade confirms the unique advantage of mid-cap companies during economic transitions—combining growth potential with earnings stability.
$HUTCHMED(00013)$ With over 10 billion in cash and plenty of room to run, plus short-term catalysts kicking in，this one’s ready to pop! Went straight to a 20% position this morning. Bull or bear? We’ll know in the next 3 days.
$RLX Technology(RLX)$ is really a treasure stock that is underestimated by the market. Tightened regulation is not a bad thing. On the contrary, it cleans up illegal brands, which is beneficial to compliant leaders like RLX, which is equivalent to making way for it. The domestic market is steadily climbing, and overseas sales are also starting to take off. The key point is that it has not yet entered the US market! It is not afraid of the Sino-US tariffs at all. It is a pure growth stock. E-cigarettes are a globally recognized harm reduction category. As the largest tobacco market, China's policies are becoming more and more rational. In the future, it will only be more standardized and pay more attention to the leaders. Do you think RLX has a chan
$HUTCHMED(00013)$ delivered a strong performance in fiscal year 2024, exceeding expectations, driven by the robust international sales growth of fruquintinib. Looking ahead, we are highly confident in HUTCHMED’s 2025 oncology business target of $350M–$450M, with overall portfolio sales expected to grow 35% YoY in FY2025. Fundamentals remain solid—maintaining a buy rating. I'll wait for stabilization before adding 10,000 more shares, holding long-term for bigger gains!
$XIAOMI-W(01810)$ has really impressed me this time! The trillion-dollar market cap was just the beginning, and now it’s hit a new high of 1.2 trillion in such a short period. Lei Jun is amazing! He’s not only overturning the expectations of Mi fans, but also showing us a whole new level of innovation and leadership.